Table of Contents Author Guidelines Submit a Manuscript
Scientifica
Volume 2012, Article ID 106576, 17 pages
http://dx.doi.org/10.6064/2012/106576
Review Article

The Molecular Genetics and Cellular Mechanisms Underlying Pulmonary Arterial Hypertension

School of Life Sciences, Faculty of Science, University of Lincoln, Brayford Pool, Lincoln LN6 7TS, UK

Received 10 October 2012; Accepted 19 November 2012

Academic Editors: J. A. Castro and B. Witzenbichler

Copyright © 2012 Rajiv D. Machado. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. C. Parera, M. van Dooren, M. van Kempen et al., “Distal angiogenesis: a new concept for lung vascular morphogenesis,” American Journal of Physiology, vol. 288, no. 1, pp. L141–L149, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. S. M. Hall, A. A. Hislop, and S. G. Haworth, “Origin, differentiation, and maturation of human pulmonary veins,” American Journal of Respiratory Cell and Molecular Biology, vol. 26, no. 3, pp. 333–340, 2002. View at Google Scholar · View at Scopus
  3. D. E. deMello and L. M. Reid, “Embryonic and early fetal development of human lung vasculature and its functional implications,” Pediatric and Developmental Pathology, vol. 3, no. 5, pp. 439–449, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Galambos and D. E. deMello, “Molecular mechanisms of pulmonary vascular development,” Pediatric and Developmental Pathology, vol. 10, no. 1, pp. 1–17, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Yamamoto, E. Jun Yun, H. P. Gerber, N. Ferrara, J. A. Whitsett, and T. H. Vu, “Epithelial-vascular cross talk mediated by VEGF-A and HGF signaling directs primary septae formation during distal lung morphogenesis,” Developmental Biology, vol. 308, no. 1, pp. 44–53, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Carmeliet, V. Ferreira, G. Breier et al., “Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele,” Nature, vol. 380, no. 6573, pp. 435–439, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Morbidelli, C. H. O. Chang, J. G. Douglas, H. J. Granger, F. Ledda, and M. Ziche, “Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium,” American Journal of Physiology, vol. 270, no. 1, part 2, pp. H411–H415, 1996. View at Google Scholar · View at Scopus
  8. H. He, V. J. Venema, X. Gu, R. C. Venema, M. B. Marrero, and R. B. Caldwell, “Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through Flk-1/KDR activation of c-Src,” The Journal of Biological Chemistry, vol. 274, no. 35, pp. 25130–25135, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Southwood, T. K. Jeffery, X. Yang et al., “Regulation of bone morphogenetic protein signalling in human pulmonary vascular development,” Journal of Pathology, vol. 214, no. 1, pp. 85–95, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Suri, P. F. Jones, S. Patan et al., “Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis,” Cell, vol. 87, no. 7, pp. 1171–1180, 1996. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Rasanen, D. C. Wood, S. Weiner, A. Ludomirski, and J. C. Huhta, “Role of the pulmonary circulation in the distribution of human fetal cardiac output during the second half of pregnancy,” Circulation, vol. 94, no. 5, pp. 1068–1073, 1996. View at Google Scholar · View at Scopus
  12. A. M. Rudolph, “Aortopulmonary transposition in the fetus: speculation on pathophysiology and therapy,” Pediatric Research, vol. 61, no. 3, pp. 375–380, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Kiserud, “Physiology of the fetal circulation,” Seminars in Fetal and Neonatal Medicine, vol. 10, no. 6, pp. 493–503, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. S. K. Sinha and S. M. Donn, “Fetal-to-neonatal maladaptation,” Seminars in Fetal and Neonatal Medicine, vol. 11, no. 3, pp. 166–173, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. A. J. Moss, G. Emmanouilides, and E. R. Duffie Jr., “Closure of the ductus arteriosus in the newborn infant,” Pediatrics, vol. 32, pp. 25–30, 1963. View at Google Scholar · View at Scopus
  16. B. Van Overmeire and S. Chemtob, “The pharmacologic closure of the patent ductus arteriosus,” Seminars in Fetal and Neonatal Medicine, vol. 10, no. 2, pp. 177–184, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. S. G. Haworth, S. M. Hall, M. Chew, and K. Allen, “Thinning of fetal pulmonary arterial wall and postnatal remodelling: ultrastructural studies on the respiratory unit arteries of the pig,” Virchows Archiv A, vol. 411, no. 2, pp. 161–171, 1987. View at Google Scholar · View at Scopus
  18. S. G. Haworth and A. A. Hislop, “Pulmonary vascular development: normal values of peripheral vascular structure,” American Journal of Cardiology, vol. 52, no. 5, pp. 578–583, 1983. View at Google Scholar · View at Scopus
  19. A. Hislop, “Developmental biology of the pulmonary circulation,” Paediatric Respiratory Reviews, vol. 6, no. 1, pp. 35–43, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. S. G. Haworth and A. A. Hislop, “Lung development—the effects of chronic hypoxia,” Seminars in Neonatology, vol. 8, no. 1, pp. 1–8, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. J. R. Runo and J. E. Loyd, “Primary pulmonary hypertension,” The Lancet, vol. 361, no. 9368, pp. 1533–1544, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Galiè, M. M. Hoeper, M. Humbert et al., “Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT),” European Heart Journal, vol. 30, no. 20, pp. 2493–2537, 2009. View at Google Scholar
  23. V. V. McLaughlin, S. L. Archer, D. B. Badesch et al., “ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association,” Journal of the American College of Cardiology, vol. 53, no. 17, pp. 1573–1619, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. J. E. Loyd, M. G. Butler, T. M. Foroud, P. M. Conneally, J. A. Phillips III, and J. H. Newman, “Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 152, no. 1, pp. 93–97, 1995. View at Google Scholar · View at Scopus
  25. E. D. Austin, J. E. Loyd, and J. A. Phillips III, “Genetics of pulmonary arterial hypertension,” Seminars in Respiratory and Critical Care Medicine, vol. 30, no. 4, pp. 386–398, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Simonneau, I. M. Robbins, M. Beghetti et al., “Updated clinical classification of pulmonary hypertension,” Journal of the American College of Cardiology, vol. 54, no. 1, supplement, pp. S43–S54, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Simonneau, N. Galiè, L. J. Rubin et al., “Clinical classification of pulmonary hypertension,” Journal of the American College of Cardiology, vol. 43, no. 12, supplement, pp. 5S–12S, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. J. E. Loyd, J. B. Atkinson, G. G. Pietra, R. Virmani, and J. H. Newman, “Heterogeneity of pathologic lesions in familial primary pulmonary hypertension,” American Review of Respiratory Disease, vol. 138, no. 4, pp. 952–957, 1988. View at Google Scholar · View at Scopus
  29. R. M. Tuder, M. Chacon, L. Alger et al., “Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis,” Journal of Pathology, vol. 195, no. 3, pp. 367–374, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. R. M. Tuder, B. Groves, D. B. Badesch, and N. F. Voelkel, “Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension,” American Journal of Pathology, vol. 144, no. 2, pp. 275–285, 1994. View at Google Scholar · View at Scopus
  31. M. E. Yeager, G. R. Halley, H. A. Golpon, N. F. Voelkel, and R. M. Tuder, “Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension,” Circulation Research, vol. 88, no. 1, pp. E2–E11, 2001. View at Google Scholar · View at Scopus
  32. R. D. Machado, V. James, M. Southwood et al., “Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension,” Circulation, vol. 111, no. 5, pp. 607–613, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. B. W. Christman, C. D. McPherson, J. H. Newman et al., “An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension,” The New England Journal of Medicine, vol. 327, no. 2, pp. 70–75, 1992. View at Google Scholar · View at Scopus
  34. K. G. Kreymborg, S. Uchida, P. Gellert et al., “Identification of right heart-enriched genes in a murine model of chronic outflow tract obstruction,” Journal of Molecular and Cellular Cardiology, vol. 49, no. 4, pp. 598–605, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Wharton, J. W. Strange, G. M. O. Møller et al., “Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells,” American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 1, pp. 105–113, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. C. E. Sparacino-Watkins, Y. C. Lai, and M. T. Gladwin, “Nitrate-nitrite-nitric oxide pathway in pulmonary arterial hypertension therapeutics,” Circulation, vol. 125, no. 23, pp. 2824–2826, 2012. View at Google Scholar
  37. M. Humbert, G. Monti, F. Brenot et al., “Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 151, no. 5, pp. 1628–1631, 1995. View at Google Scholar · View at Scopus
  38. T. Itoh, N. Nagaya, H. Ishibashi-Ueda et al., “Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension,” Respirology, vol. 11, no. 2, pp. 158–163, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. R. M. Tuder and N. F. Voelkel, “Pulmonary hypertension and inflammation,” Journal of Laboratory and Clinical Medicine, vol. 132, no. 1, pp. 16–24, 1998. View at Google Scholar · View at Scopus
  40. P. M. Hassoun, L. Mouthon, J. A. Barberà et al., “Inflammation, growth factors, and pulmonary vascular remodeling,” Journal of the American College of Cardiology, vol. 54, no. 1, supplement, pp. S10–S19, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. X. J. Yuan, J. Wang, M. Juhaszova, S. P. Gaine, and L. J. Rubin, “Attenuated K+ channel gene transcription in primary pulmonary hypertension,” The Lancet, vol. 351, no. 9104, pp. 726–727, 1998. View at Publisher · View at Google Scholar · View at Scopus
  42. P. Herve, L. Drouet, C. Dosquet et al., “Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin,” American Journal of Medicine, vol. 89, no. 1, pp. 117–120, 1990. View at Publisher · View at Google Scholar · View at Scopus
  43. M. R. MacLean, P. Herve, S. Eddahibi, and S. Adnot, “5-Hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension,” British Journal of Pharmacology, vol. 131, no. 2, pp. 161–168, 2000. View at Google Scholar · View at Scopus
  44. C. Guignabert, M. Izikki, L. I. Tu et al., “Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension,” Circulation Research, vol. 98, no. 10, pp. 1323–1330, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. J. P. Bayley and P. Devilee, “The Warburg effect in 2012,” Current Opinion in Oncology, vol. 24, no. 1, pp. 62–67, 2012. View at Google Scholar
  46. S. L. Archer, E. D. Michelakis, B. Thébaud et al., “A central role for oxygen-sensitive K+ channels and mitochondria in the specialized oxygen-sensing system,” Novartis Foundation Symposium, vol. 272, pp. 157–171, 2006. View at Google Scholar · View at Scopus
  47. S. L. Archer, M. Gomberg-Maitland, M. L. Maitland, S. Rich, J. G. N. Garcia, and E. K. Weir, “Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1α-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer,” American Journal of Physiology, vol. 294, no. 2, pp. H570–H578, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Rabinovitch, “Pathobiology of pulmonary hypertension: extracellular matrix,” Clinics in Chest Medicine, vol. 22, no. 3, pp. 433–449, 2001. View at Publisher · View at Google Scholar · View at Scopus
  49. D. T. Dresdale, M. Schultz, and R. J. Michtom, “Primary pulmonary hypertension. I. Clinical and hemodynamic study,” The American Journal of Medicine, vol. 11, no. 6, pp. 686–705, 1951. View at Google Scholar · View at Scopus
  50. S. Rich, D. R. Dantzker, S. M. Ayres et al., “Primary pulmonary hypertension. A national prospective study,” Annals of Internal Medicine, vol. 107, no. 2, pp. 216–223, 1987. View at Google Scholar
  51. J. H. Morse, A. C. Jones, R. J. Barst et al., “Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32,” Circulation, vol. 95, no. 12, pp. 2603–2606, 1997. View at Google Scholar
  52. W. C. Nichols, D. L. Koller, B. Slovis et al., “Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32,” Nature Genetics, vol. 15, no. 3, pp. 277–280, 1997. View at Publisher · View at Google Scholar · View at Scopus
  53. R. D. Machado, M. W. Pauciulo, N. Fretwell et al., “A physical and transcript map based upon refinement of the critical interval for PPH1, a gene for familial primary pulmonary hypertension,” Genomics, vol. 68, no. 2, pp. 220–228, 2000. View at Publisher · View at Google Scholar · View at Scopus
  54. K. B. Lane, R. D. Machado, M. W. Pauciulo et al., “Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension,” Nature Genetics, vol. 26, no. 1, pp. 81–84, 2000. View at Publisher · View at Google Scholar · View at Scopus
  55. Z. Deng, J. H. Morse, S. L. Slager et al., “Familial primary pulmonary hypertension (Gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene,” American Journal of Human Genetics, vol. 67, no. 3, pp. 737–744, 2000. View at Publisher · View at Google Scholar · View at Scopus
  56. K. Miyazono, Y. Kamiya, and M. Morikawa, “Bone morphogenetic protein receptors and signal transduction,” Journal of Biochemistry, vol. 147, no. 1, pp. 35–51, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. J. R. Thomson, R. D. Machado, M. W. Pauciulo et al., “Sporadiac primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family,” Journal of Medical Genetics, vol. 37, no. 10, pp. 741–745, 2000. View at Google Scholar · View at Scopus
  58. R. Koehler, E. Grünig, M. W. Pauciulo et al., “Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension,” Journal of Medical Genetics, vol. 41, no. 12, article e127, 2004. View at Google Scholar · View at Scopus
  59. H. Morisaki, N. Nakanishi, S. Kyotani, A. Takashima, H. Tomoike, and T. Morisaki, “BMPR2 mutations found in Japanese patients with familial and sporadic primary pulmonary hypertension,” Human Mutation, vol. 23, no. 6, p. 632, 2004. View at Google Scholar · View at Scopus
  60. J. H. Newman, R. C. Trembath, J. A. Morse et al., “Genetic basis of pulmonary arterial hypertension: current understanding and future directions,” Journal of the American College of Cardiology, vol. 43, no. 12, supplement, pp. 33S–39S, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. M. A. Aldred, R. D. Machado, V. James, N. W. Morrell, and R. C. Trembath, “Characterization of the BMPR2 5′-untranslated region and a novel mutation in pulmonary hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 8, pp. 819–824, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. F. Liu, F. Ventura, J. Doody, and J. Massague, “Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs,” Molecular and Cellular Biology, vol. 15, no. 7, pp. 3479–3486, 1995. View at Google Scholar · View at Scopus
  63. J. Massague, “TGF-beta signal transduction,” Annual Review of Biochemistry, vol. 67, pp. 753–791, 1998. View at Google Scholar
  64. L. David, J. J. Feige, and S. Bailly, “Emerging role of bone morphogenetic proteins in angiogenesis,” Cytokine and Growth Factor Reviews, vol. 20, no. 3, pp. 203–212, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. R. D. Machado, N. Rudarakanchana, C. Atkinson et al., “Functional interaction between BMPR-II and Tctex-1, a light chain of dynein, is isoform-specific and disrupted by mutations underlying primary pulmonary hypertension,” Human Molecular Genetics, vol. 12, no. 24, pp. 3277–3286, 2003. View at Publisher · View at Google Scholar · View at Scopus
  66. V. C. Foletta, M. A. Lim, J. Soosairaiah et al., “Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1,” Journal of Cell Biology, vol. 162, no. 6, pp. 1089–1098, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. A. Zakrzewicz, M. Hecker, L. M. Marsh et al., “Receptor for activated C-kinase 1, a novel interaction partner of type II bone morphogenetic protein receptor, regulates smooth muscle cell proliferation in pulmonary arterial hypertension,” Circulation, vol. 115, no. 23, pp. 2957–2968, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. K. Ihida-Stansbury, D. M. McKean, K. B. Lane et al., “Tenascin-C is induced by mutated BMP type II receptors in familial forms of pulmonary arterial hypertension,” American Journal of Physiology, vol. 291, no. 4, pp. L694–L702, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Nohe, E. Keating, P. Knaus, and N. O. Petersen, “Signal transduction of bone morphogenetic protein receptors,” Cellular Signalling, vol. 16, no. 3, pp. 291–299, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Hartung, K. Bitton-Worms, M. M. Rechtman et al., “Different routes of bone morphogenic protein (BMP) receptor endocytosis influence BMP signaling,” Molecular and Cellular Biology, vol. 26, no. 20, pp. 7791–7805, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Nohe, S. Hassel, M. Ehrlich et al., “The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways,” The Journal of Biological Chemistry, vol. 277, no. 7, pp. 5330–5338, 2002. View at Publisher · View at Google Scholar · View at Scopus
  72. R. D. Machado, O. Eickelberg, C. G. Elliott et al., “Genetics and genomics of pulmonary arterial hypertension,” Journal of the American College of Cardiology, vol. 54, no. 1, supplement, pp. S32–S42, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. R. D. Machado, M. A. Aldred, V. James et al., “Mutations of the TGF-β type II receptor BMPR2 in pulmonary arterial hypertension,” Human Mutation, vol. 27, no. 2, pp. 121–132, 2006. View at Publisher · View at Google Scholar · View at Scopus
  74. E. D. Austin, J. A. Phillips, J. D. Cogan et al., “Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension,” Respiratory Research, vol. 10, article 87, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. R. D. Machado, M. W. Pauciulo, J. R. Thomson et al., “BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension,” American Journal of Human Genetics, vol. 68, no. 1, pp. 92–102, 2001. View at Publisher · View at Google Scholar · View at Scopus
  76. J. Greenwald, W. H. Fischer, W. W. Vale, and S. Choe, “Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase,” Nature Structural Biology, vol. 6, no. 1, pp. 18–22, 1999. View at Publisher · View at Google Scholar · View at Scopus
  77. N. Rudarakanchana, J. A. Flanagan, H. Chen et al., “Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension,” Human Molecular Genetics, vol. 11, no. 13, pp. 1517–1525, 2002. View at Google Scholar · View at Scopus
  78. S. K. Hanks and T. Hunter, “Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification,” The FASEB Journal, vol. 9, no. 8, pp. 576–596, 1995. View at Google Scholar · View at Scopus
  79. A. Nishihara, T. Watabe, T. Imamura, and K. Miyazono, “Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension,” Molecular Biology of the Cell, vol. 13, no. 9, pp. 3055–3063, 2002. View at Publisher · View at Google Scholar · View at Scopus
  80. T. Yasuda, Y. Tada, N. Tanabe, K. Tatsumi, and J. West, “Rho-kinase inhibition alleviates pulmonary hypertension in transgenic mice expressing a dominant-negative type II bone morphogenetic protein receptor gene,” American Journal of Physiology, vol. 301, no. 5, pp. 667–674, 2011. View at Google Scholar
  81. M. T. Nasim, T. Ogo, H. M. Chowdhury et al., “BMPR-II deficiency elicits pro-proliferative and anti-apoptotic responses through the activation of TGFbeta-TAK1-MAPK pathways in PAH,” Human Molecular Genetics, vol. 21, no. 11, pp. 2548–2558, 2012. View at Google Scholar
  82. R. J. Davies, A. M. Holmes, J. Deighton et al., “BMP type II receptor deficiency confers resistance to growth inhibition by TGF-beta in pulmonary artery smooth muscle cells: role of proinflammatory cytokines,” American Journal of Physiology, vol. 302, no. 6, pp. L604–L615, 2012. View at Google Scholar
  83. M. Sankelo, J. A. Flanagan, R. Machado et al., “BMPR2 mutations have short lifetime expectancy in primary pulmonary hypertension,” Human Mutation, vol. 26, no. 2, pp. 119–124, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. C. G. Elliott, E. W. Glissmeyer, G. T. Havlena et al., “Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension,” Circulation, vol. 113, no. 21, pp. 2509–2515, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. D. Liu, W. H. Wu, Y. M. Mao et al., “BMPR2 mutations influence phenotype more obviously in male patients with pulmonary arterial hypertension,” Circulation, vol. 5, no. 5, pp. 511–518, 2012. View at Google Scholar
  86. J. Cogan, E. Austin, L. Hedges et al., “Role of BMPR2 alternative splicing in HPAH penetrance,” Circulation, vol. 126, no. 15, pp. 1907–1916, 2012. View at Google Scholar
  87. J. McDonald, P. Bayrak-Toydemir, and R. E. Pyeritz, “Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis,” Genetics in Medicine, vol. 13, no. 7, pp. 607–616, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. K. A. McAllister, K. M. Grogg, D. W. Johnson et al., “Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1,” Nature Genetics, vol. 8, no. 4, pp. 345–351, 1994. View at Publisher · View at Google Scholar · View at Scopus
  89. D. W. Johnson, J. N. Berg, M. A. Baldwin et al., “Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type,” Nature Genetics, vol. 13, no. 2, pp. 189–195, 1996. View at Google Scholar · View at Scopus
  90. G. M. F. Wallace and C. L. Shovlin, “A hereditary haemorrhagic telangiectasia family with pulmonary involvement is unlinked to the known HHT genes, endoglin and ALK-1,” Thorax, vol. 55, no. 8, pp. 685–690, 2000. View at Publisher · View at Google Scholar · View at Scopus
  91. C. L. Shovlin and M. Letarte, “Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms,” Thorax, vol. 54, no. 8, pp. 714–729, 1999. View at Google Scholar · View at Scopus
  92. S. A. Abdalla, N. Pece-Barbara, S. Vera et al., “Analysis of ALK-1 and endoglin in newborns from families with hereditary hemorrhagic telangiectasia type 2,” Human Molecular Genetics, vol. 9, no. 8, pp. 1227–1237, 2000. View at Google Scholar · View at Scopus
  93. R. E. Harrison, J. A. Flanagan, M. Sankelo et al., “Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia,” Journal of Medical Genetics, vol. 40, no. 12, pp. 865–871, 2003. View at Google Scholar · View at Scopus
  94. S. A. Abdalla, U. Cymerman, D. Rushlow et al., “Novel mutations and polymorphisms in genes causing hereditary hemorrhagic telangiectasia,” Human Mutation, vol. 25, no. 3, pp. 320–321, 2005. View at Google Scholar · View at Scopus
  95. A. Chida, M. Shintani, H. Yagi et al., “Outcomes of childhood pulmonary arterial hypertension in BMPR2 and ALK1 mutation carriers,” American Journal of Cardiology, vol. 110, no. 4, pp. 586–593, 2012. View at Google Scholar
  96. M. Shintani, H. Yagi, T. Nakayama, T. Saji, and R. Matsuoka, “A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension,” Journal of Medical Genetics, vol. 46, no. 5, pp. 331–337, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. M. T. Nasim, T. Ogo, M. Ahmed et al., “Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension,” Human Mutation, vol. 32, no. 12, pp. 1385–1389, 2011. View at Google Scholar
  98. Z. Huang, D. Wang, K. Ihida-Stansbury, P. L. Jones, and J. F. Martin, “Defective pulmonary vascular remodeling in Smad8 mutant mice,” Human Molecular Genetics, vol. 18, no. 15, pp. 2791–2801, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. A. Chida, M. Shintani, T. Nakayama et al., “Missense mutations of the BMPR1B (ALK6) gene in childhood idiopathic pulmonary arterial hypertension,” Circulation Journal, vol. 76, no. 6, pp. 1501–1508, 2012. View at Google Scholar
  100. N. A. Maniatis, V. Shinin, D. E. Schraufnagel et al., “Increased pulmonary vascular resistance and defective pulmonary artery filling in caveolin-1-/- mice,” American Journal of Physiology, vol. 294, no. 5, pp. L865–L873, 2008. View at Publisher · View at Google Scholar · View at Scopus
  101. E. D. Austin, L. Ma, C. LeDuc et al., “Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension,” Circulation, vol. 5, no. 3, pp. 336–343, 2012. View at Google Scholar
  102. W. T. Abraham, M. V. Raynolds, D. B. Badesch et al., “Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 4, no. 1, pp. 27–30, 2003. View at Google Scholar · View at Scopus
  103. M. M. Hoeper, A. Tacacs, U. Stellmacher, and R. Lichtinghagen, “Lack of association between angiotensin converting enzyme (ACE) genotype, serum ACE activity, and haemodynamics in patients with primary pulmonary hypertension,” Heart, vol. 89, no. 4, pp. 445–446, 2003. View at Google Scholar · View at Scopus
  104. A. A. Aldashev, A. S. Sarybaev, A. S. Sydykov et al., “Characterization of high-altitude pulmonary hypertension in the Kyrgyz: association with angiotensin-converting enzyme genotype,” American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 10, pp. 1396–1402, 2002. View at Publisher · View at Google Scholar · View at Scopus
  105. S. Eddahibi, M. Humbert, E. Fadel et al., “Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension,” The Journal of Clinical Investigation, vol. 108, no. 8, pp. 1141–1150, 2001. View at Publisher · View at Google Scholar · View at Scopus
  106. R. D. Machado, R. Koehler, E. Glissmeyer et al., “Genetic association of the serotonin transporter in pulmonary arterial hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 7, pp. 793–797, 2006. View at Publisher · View at Google Scholar · View at Scopus
  107. E. D. Willers, J. H. Newman, J. E. Loyd et al., “Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 7, pp. 798–802, 2006. View at Publisher · View at Google Scholar · View at Scopus
  108. C. V. Remillard, D. D. Tigno, O. Platoshyn et al., “Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension,” American Journal of Physiology, vol. 292, no. 5, pp. C1837–C1853, 2007. View at Publisher · View at Google Scholar · View at Scopus
  109. R. Koehler, H. Olschewski, M. Hoeper, B. Janssen, and E. Grünig, “Serotonin transporter gene polymorphism in a cohort of German patients with idiopathic pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension,” Chest, vol. 128, no. 6, supplement, p. 619, 2005. View at Publisher · View at Google Scholar · View at Scopus
  110. J. Rehman and S. L. Archer, “A proposed mitochondrial-metabolic mechanism for initiation and maintenance of pulmonary arterial hypertension in fawn-hooded rats: the warburg model of pulmonary arterial hypertension,” Advances in Experimental Medicine and Biology, vol. 661, pp. 171–185, 2010. View at Publisher · View at Google Scholar · View at Scopus
  111. H. Beppu, M. Kawabata, T. Hamamoto et al., “BMP type II receptor is required for gastrulation and early development of mouse embryos,” Developmental Biology, vol. 221, no. 1, pp. 249–258, 2000. View at Publisher · View at Google Scholar · View at Scopus
  112. E. C. Délot, M. E. Bahamonde, M. Zhao, and K. M. Lyons, “BMP signaling is required for septation of the outflow tract of the mammalian heart,” Development, vol. 130, no. 1, pp. 209–220, 2003. View at Publisher · View at Google Scholar · View at Scopus
  113. P. Caruso, Y. Dempsie, H. C. Stevens et al., “A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples,” Circulation Research, vol. 111, no. 3, pp. 290–300, 2012. View at Google Scholar
  114. J. West, K. Fagan, W. Steudel et al., “Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle,” Circulation Research, vol. 94, no. 8, pp. 1109–1114, 2004. View at Publisher · View at Google Scholar · View at Scopus
  115. J. West, J. Harral, K. Lane et al., “Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions,” American Journal of Physiology, vol. 295, no. 5, pp. L744–L755, 2008. View at Publisher · View at Google Scholar · View at Scopus
  116. C. Atkinson, S. Stewart, P. D. Upton et al., “Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor,” Circulation, vol. 105, no. 14, pp. 1672–1678, 2002. View at Publisher · View at Google Scholar · View at Scopus
  117. R. J. Barst, J. S. R. Gibbs, H. A. Ghofrani et al., “Updated evidence-based treatment algorithm in pulmonary arterial hypertension,” Journal of the American College of Cardiology, vol. 54, no. 1, supplement, pp. S78–S84, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. N. Galiè, A. Manes, and A. Branzi, “Prostanoids for pulmonary arterial hypertension,” American Journal of Respiratory Medicine, vol. 2, no. 2, pp. 123–137, 2003. View at Google Scholar · View at Scopus
  119. O. Sitbon, M. Humbert, H. Nunes et al., “Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival,” Journal of the American College of Cardiology, vol. 40, no. 4, pp. 780–788, 2002. View at Publisher · View at Google Scholar · View at Scopus
  120. A. K. Doran, D. D. Ivy, R. J. Barst, N. Hill, S. Murali, and R. L. Benza, “Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension,” International Journal of Clinical Practice. Supplement, no. 160, pp. 5–9, 2008. View at Google Scholar · View at Scopus
  121. V. V. McLaughlin, A. Shillington, and S. Rich, “Survival in primary pulmonary hypertension: the impact of epoprostenol therapy,” Circulation, vol. 106, no. 12, pp. 1477–1482, 2002. View at Publisher · View at Google Scholar · View at Scopus
  122. Centers for Disease Control and Prevention CDC, “Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension—seven sites, United States, 2003—2006,” Morbidity and Mortality Weekly Report (MMWR), vol. 56, no. 8, pp. 170–172, 2007. View at Google Scholar
  123. H. Olschewski, G. Simonneau, N. Galiè et al., “Inhaled iloprost for severe pulmonary hypertension,” The New England Journal of Medicine, vol. 347, no. 5, pp. 322–329, 2002. View at Publisher · View at Google Scholar · View at Scopus
  124. N. Galiè, L. Rubin, M. Hoeper et al., “Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial,” The Lancet, vol. 371, no. 9630, pp. 2093–2100, 2008. View at Publisher · View at Google Scholar · View at Scopus
  125. L. J. Rubin, D. B. Badesch, R. J. Barst et al., “Bosentan therapy for pulmonary arterial hypertension,” The New England Journal of Medicine, vol. 346, no. 12, pp. 896–903, 2002. View at Publisher · View at Google Scholar · View at Scopus
  126. N. Galiè, H. Olschewski, R. J. Oudiz et al., “Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-Blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2,” Circulation, vol. 117, no. 23, pp. 3010–3019, 2008. View at Publisher · View at Google Scholar · View at Scopus
  127. J. K. Olsson, R. T. Zamanian, J. A. Feinstein, and R. L. Doyle, “Surgical and interventional therapies for pulmonary arterial hypertension,” Seminars in Respiratory and Critical Care Medicine, vol. 26, no. 4, pp. 417–428, 2005. View at Publisher · View at Google Scholar · View at Scopus
  128. G. Simonneau, L. J. Rubin, N. Galiè et al., “Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial,” Annals of Internal Medicine, vol. 149, no. 8, pp. 521–530, 2008. View at Google Scholar · View at Scopus
  129. E. P. Trulock, L. B. Edwards, D. O. Taylor, M. M. Boucek, B. M. Keck, and M. I. Hertz, “Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report—2006,” Journal of Heart and Lung Transplantation, vol. 25, no. 8, pp. 880–892, 2006. View at Publisher · View at Google Scholar · View at Scopus
  130. R. L. Benza, D. P. Miller, M. Gomberg-Maitland et al., “Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL),” Circulation, vol. 122, no. 2, pp. 164–172, 2010. View at Publisher · View at Google Scholar · View at Scopus
  131. M. Humbert, O. Sitbon, A. Chaouat et al., “Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era,” Circulation, vol. 122, no. 2, pp. 156–163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  132. A. M. Reynolds, M. D. Holmes, S. M. Danilov, and P. N. Reynolds, “Targeted gene delivery of BMPR2 attenuates pulmonary hypertension,” European Respiratory Journal, vol. 39, no. 2, pp. 329–343, 2012. View at Google Scholar
  133. M. Kataoka, T. Kawakami, Y. Tamura et al., “Gene transfer therapy by either type 1 or type 2 adeno-associated virus expressing human prostaglandin I2 synthase gene is effective for treatment of pulmonary arterial hypertension,” Journal of Cardiovascular Pharmacology and Therapeutics. In press. View at Publisher · View at Google Scholar